U. STOJILJKOVIC, C. MEYER, P. BOULAY, P. HEBEISEN, D. RAGEOT, M. WYMANN*, C. BORSARI* (UNIVERSITY OF BASEL, SWITZERLAND) Stereospecific Synthesis of Substituted Sulfamidates as Privileged Morpholine Building Blocks Synthesis **2022**, DOI: 10.1055/a-1915-7794.

Synthesis of Versatile Enantiopure Morpholine Fragments from Chiral-Pool Starting Materials



Category

Synthesis of Heterocycles

Key words

morpholines

cyclic sulfamidates

chiral pool

building blocks

bioisosterism

asymmetric synthesis

Synfact of the Month

Significance: The favorable physicochemical properties of morpholines make them attractive motifs for incorporation into bioactive molecules, often as bioisosteric replacements for piperidines; this is a common strategy owing, not only to the lower basicity of the nitrogen, but also because the CYP-mediated degradation of the morpholine ring often leads to nontoxic metabolites. The current report describes methods for synthesizing enantiopure functionalized morpholine fragments, with the 3-hydroxymethylmorpholines **5–8** featuring two nucleophilic groups, whereas the corresponding sulfamidates **1–4** can be viewed as aziridine equivalents and used in annulation reactions for the introduction of morpholine moieties.

Comment: The integral stereochemistry of the desired building blocks is imparted through appropriate selection of readily available enantiopure starting materials specifically derived from Bocprotected serine (e.g., 9) or 1,2-propanediol (e.g., 12). Optimization studies involving the selection of a suitable base-solvent combination were carried out for the critical ring opening of the cyclic sulfamidate 11 with diol 12; aqueous citric acid was used to cleave the resulting sulfamate intermediate. Sulfamidates 1-3 were synthesized in ~10% yield over seven steps (three chromatographic purifications) whereas the dimethyl-substituted derivative 4 was obtained in a similar yield, also in seven steps, but with four chromatographic purifications; a double-Grignard addition to a readily available lactam served as the key step in this synthesis.

 SYNFACTS Contributors: Paul Richardson (Pfizer)

 Synfacts 2022, 18(11), 1177
 Published online: 18.10.2022

 DOI: 10.1055/s-0042-1753032; Reg-No.: V11622SF